Wellington Management Group LLP Purchases 122,402 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Wellington Management Group LLP grew its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 26.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 585,594 shares of the company's stock after buying an additional 122,402 shares during the period. Wellington Management Group LLP owned approximately 0.29% of Taysha Gene Therapies worth $1,013,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of TSHA. Avoro Capital Advisors LLC increased its position in shares of Taysha Gene Therapies by 7.2% during the fourth quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company's stock valued at $34,600,000 after acquiring an additional 1,349,999 shares in the last quarter. Octagon Capital Advisors LP boosted its stake in Taysha Gene Therapies by 128.6% during the 4th quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company's stock valued at $18,078,000 after purchasing an additional 5,877,778 shares during the last quarter. Vanguard Group Inc. boosted its stake in Taysha Gene Therapies by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company's stock valued at $15,409,000 after purchasing an additional 641,305 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of Taysha Gene Therapies in the 4th quarter worth $8,650,000. Finally, Geode Capital Management LLC increased its holdings in shares of Taysha Gene Therapies by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock worth $6,182,000 after purchasing an additional 9,591 shares in the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Taysha Gene Therapies

In related news, major shareholder Paul B. Manning bought 750,000 shares of the stock in a transaction that occurred on Friday, May 30th. The shares were bought at an average cost of $2.75 per share, for a total transaction of $2,062,500.00. Following the completion of the transaction, the insider now owns 2,841,704 shares of the company's stock, valued at approximately $7,814,686. This trade represents a 35.86% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Chardan Capital upped their price target on Taysha Gene Therapies from $7.00 to $9.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Canaccord Genuity Group boosted their target price on Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, June 3rd. Citigroup reaffirmed an "outperform" rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Finally, Needham & Company LLC restated a "buy" rating and set a $8.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $7.57.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA traded down $0.19 on Tuesday, hitting $2.61. The stock had a trading volume of 2,577,077 shares, compared to its average volume of 3,047,193. The business's 50-day simple moving average is $2.10 and its two-hundred day simple moving average is $1.93. The stock has a market cap of $560.27 million, a price-to-earnings ratio of 4.14 and a beta of 1.04. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $4.32. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.08). The company had revenue of $2.30 million for the quarter, compared to the consensus estimate of $1.48 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. During the same quarter last year, the firm posted ($0.10) earnings per share. As a group, research analysts predict that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.